Vermillion Q2 Revenues Dip 9 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion reported today a 9 percent drop year over year in second-quarter revenues as licensing revenues retreated 62 percent.

For the three months ended June 30, total revenues were $304,000, down from $344,000 a year ago. While product revenues — comprised completely of sales of the company's OVA1 ovarian cancer test — rose more than 300 percent year over year to $191,000 from $45,000, license revenues fell to $113,000 from $299,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.